Cytek Biosciences (CTKB) revenue breakdown
By product, Product is the largest at 72% of fiscal 2025 revenue; Service grew fastest, 50% a year over 5 years.
By region, United States is the largest at 47% of fiscal 2025 revenue; APAC grew fastest, 31% a year over 5 years.
Revenue by product
Fiscal years, as Cytek Biosciences reports them in its 10-K filings; fiscal 2025 total $201M.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Product | $85M | $120M | $149M | $157M | $153M | $144M | 72% |
| Service | $8M | $8M | $15M | $36M | $47M | $57M | 28% |
Revenue by region
Fiscal years, as Cytek Biosciences reports them in its 10-K filings; fiscal 2025 total $201M.
| Regions | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| United States | $55M | $73M | $95M | $102M | $93M | $95M | 47% |
| EMEA | $26M | $37M | $44M | $53M | $62M | $56M | 28% |
| APAC | $11M | $16M | $23M | $32M | $36M | $41M | 20% |
| Other | $710,000 | $2M | $3M | $6M | $10M | $9M | 5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CTKB.
Open CTKB in InvestinglyQuestions
Where does Cytek Biosciences make its money?
In fiscal 2025, by product: Product $144M, Service $57M.
From Cytek Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.